Hatteras Venture Partners VII, LP
Late investment period
Late investment period: first sale Dec 2021, per Form D (fund age approximates vintage)
- Vintage
- 2021
- Fund size
- $135.05M to $250M (Form D)
- Stages
- Not stated
- Sectors
- Biotech, Medical devices, Healthtech
- Regions
- Not stated
01 · Thesis
Hatteras Venture Partners invests in early-stage biotech, medtech, and healthtech companies, partnering with visionary founders to build transformative businesses that advance human medicine and benefit patients.Inferred from the firm's website
02 · Initial check
$1.35M to $4.17M (estimated from fund size)
Estimated from Form D: $135.05M sold of a $250M target
03 · Who to approach
Named on this fund's Form D
- John Crumpler, Manager of General Partner
- Jeffrey Terrell, Manager of General Partner
- Michael Dial, Manager of General Partner
- Douglas Reed, MD, General Partner
- Christy Shaffer, PhD, General Partner
- Clay B. Thorp, General Partner
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Firm-wideHatteras Venture Partners partners with visionary founders to build transformative biotech, medtech, and healthtech companies.
We partner with visionary founders to build transformative biotech, Medtech, and Healthtech ComPanies.
https://hatterasvp.com/
06 · Sources
Last verified: Oct 28, 2026